Millions of people are diagnosed with Alzheimer's disease each year, comprising 60% to 70% of dementia cases worldwide. While cognitive impairment and structural brain changes are indicative of ...
Rituximab pre-conditioning in a phase I study of CARv3-TEAM-E for recurrent glioblastoma (GBM): The INCIPIENT trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results